Neuros Medical, Inc. Secures $56 Million to Revolutionize Amputee Pain Relief and Recovery

Neuros Medical, Inc. is excited to announce a significant funding milestone with a total capital raise of $56,000,000—a critical boost that marks a transformative step forward in our mission to help amputees combat chronic phantom and residual limb pain. This recent infusion of capital will empower our dedicated research and development team as we refine and advance our novel device technology aimed at reducing pain and ultimately diminishing opioid dependency. At Neuros, we understand the immense challenges that amputees face, not only in managing physical pain but also in confronting the psychological and mental health impacts that come with chronic discomfort. The funding will be strategically allocated to accelerate product development, support clinical trials, and navigate the comprehensive regulatory landscape as we work towards obtaining FDA clearance for our investigational device. By investing in innovative solutions, our goal is to enhance quality of life by providing safe, effective, and sustainable pain management options that address both the physical and emotional aspects of recovery. This milestone is a testament to the confidence that our investors have in our vision and our commitment to revolutionizing pain management. We look forward to collaborating with clinical partners and the broader medical community as we continue to develop robust data and fine-tune our technology. While our product is pending FDA clearance and is not yet available for sale, we remain steadfast in our determination to pave the way for breakthroughs that restore hope and foster healing for amputees everywhere.